$-0.04 EPS Expected for Marrone Bio Innovations, Inc. (MBII) on May, 10

May 3, 2018 - By Carey Conley

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 0.57. That’s change of 0.21, from 2017Q3’s 0.78. 5 investors sold all, 2 reduced holdings as Marrone Bio Innovations, Inc. ratio fall. 2 rose holdings while 2 funds took holdings. Funds hold 11.74 million shares thus 0.33% less from 2017Q3’s 11.77 million shares.
Northern Corp owns 24,737 shs. Cap Planning Advsrs Limited Liability Co, a California-based fund reported 11,500 shs. Primecap Mngmt Ca has 2.63M shs for 0% of their capital. 14 were reported by Royal Bank & Trust Of Canada. 473,032 were accumulated by Vanguard Gp. Raymond James Serv Advisors Inc holds 11,061 shs or 0% of its capital. 79,220 are owned by Blackrock. Ogorek Anthony Joseph Ny Adv holds 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII) or 300 shs. Geode Cap Mgmt Ltd Liability reported 89,410 shs. Hanson Mcclain Inc invested 0% of its capital in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Waddell And Reed Financial Inc holds 0.01% of its capital in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 4.71 million shs. Ardsley Advisory Prns has 0.49% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII). The Massachusetts-based State Street Corporation has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Morgan Stanley, a New York-based fund reported 480 shs.

Marrone Bio Innovations, Inc. registered $5.00 million net activity with 1 insider purchase and 0 insider sales since February 5, 2018.

Earnings report for Marrone Bio Innovations, Inc. (NASDAQ:MBII) is awaited on May, 10., according to Zacks. Analysts expect change of 87.10 % or $0.27 from previous year’s $-0.31 earnings per share compared to current’s $-0.04 earnings per share. Wall Street predicts -83.33 % EPS growth as of May, 10. The stock decreased 0.58% or $0.01 during the last trading session, reaching $1.71.Marrone Bio Innovations, Inc. has volume of 32,825 shares. Since May 3, 2017 MBII has risen 33.33% and is uptrending. MBII outperformed the S&P500 by 21.78%.

Marrone Bio Innovations, Inc. provides bio pest management and plant health products primarily for agricultural and water markets in the United States and internationally.The company has $187.02 million market cap. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.Last it reported negative earnings. The company's products include Regalia, a plant extract fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants.

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: